Avtor/Urednik		Janžič, Andrej; Locatelli, Igor; Devetak, Andreja; Kos, Mitja
Naslov		Parametri vključevanja konjugiranih pnevmokoknih cepiv v slovenski zdravstveni sistem
Prevedeni naslov		Uptake parameters of pneumococcal conjugate vaccines into the Slovenian healthcare system
Tip		članek
Vir		Farm Vestn
Vol. in št.		Letnik 63, št. 2
Leto izdaje		2012
Obseg		str. 116-121
Jezik		slo
Abstrakt		The 7-valent pneumococcal vaccine (PCV-7) was the first conjugated vaccine registered in Europe in 2001. It was followed by two other vaccines, the 10-valent vaccine (PHiD-CV) and the 13-valent vaccine (PCV-13). These vaccinesare designed to prevent invasive pneumococcal infections, pneumonia and acute otitis media caused by Streptococcus pneumoniae. Uptake of vaccines into the Slovenian health system is being managed by the Health Council, which has identified five criteria for the evaluation of new health programs. The health effectiveness is defined as the most important criterion. The size of the problem or epidemiologic data of the disease is also considered. The criteria also include health economic parameters, with assessment of cost-effectivenes and to some extent also the budget impact of uptake of the vaccination program into the health system.
Izvleček		V Evropi je bilo 7 valentno cepivo (PCV-7), kot prvo konjugirano pnevmokokno cepivo, registrirano v letu 2001. Danes pa sta na tržišču prisotni tudi dve novejši cepivi, to sta 10-valentno cepivo (PHiD-CV) in 13-valentno cepivo (PCV-13). Ta cepiva so namenjena preprečevanju invazivnih pnevmokoknih okužb, pljučnice in akutnega vnetja srednjega ušesa, ki jih povzroča Streptococcus pneumoniae. Vključevanje cepiv v slovenski zdravstveni sistem poteka preko Zdravstvenega sveta, ki ima opredeljenih pet meril vrednotenja novih zdravstvenih programov. Kot najpomembnejše merilo je opredeljena zdravstvena učinkovitost. Pri ocenjevanju programa se vrednoti tudi obsežnost programa oziroma epidemiološki podatki o bolezni. Merila pa vključujejo tudi zdravstveno ekonomske parametre, med katerimi se vrednoti stroškovna učinkovitost in deloma tudi finančne učinke uvedbe programa cepljenja.